Nebenwirkungen · Eptifibatide Accord
Eptifibatide Accord 0.75 mg/ml solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-135138 · Präparat HOS-097660
Major bleeding was defined in the PURSUIT trial as either an intracranial haemorrhage or a decrease in haemoglobin concentrations of more than 5 g/dl. Major bleeding was also very common and reported more frequently with eptifibatide than with placebo in the PURSUIT study (> 1/10 or 10.8 % versus 9.3 %), but it was infrequent in the vast majority of patients who did not undergo CABG within 30 days of inclusion in the study. In patients undergoing CABG, the incidence of bleeding was not increased by eptifibatide compared to the patients treated with placebo. In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of eptifibatide -treated patients vs. 4.6 % of placebo- treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T01:00:00Z · SHA-256 9396fc6df1ff96694d27eb7b74981a633ad8bf93b3393c54e43ba8b1ce931773 · Passage 25b09d5abc4fbd5c8f6920026cce141a0beb415a448ed5052b075c179b9da999 · Zeichen 4099–4827 im Abschnitt